Abstract
Reproxalap is a reactive aldehyde species inhibitor. This article investigates reproxalap’s ability to control ocular inflammation in non-infectious uveitis, allergic conjunctivitis and dry eye disease. Clinical trials for reproxalap were reviewed for efficacy and tolerability. Reproxalap appears to be an effective treatment for dry eye disease, with satisfactory tolerability.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
